This inventor holds 1 USPTO granted patent. Top assignees: Novo Nordisk A/s, Zymogenetics, Inc.. Active years: 1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1,801 
1 out of 723 Years Active: 1998
Title: Hank R Franklin: Innovator in Hemostasis
Introduction
Hank R Franklin is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of biochemistry, particularly in the area of blood coagulation and fibrinolysis. His work has implications for the development of therapeutic agents aimed at enhancing the resolution of blood clots.
Latest Patents
Hank R Franklin holds a patent for a Factor XIIIA inhibitor. This compound is useful for inhibiting FXIIIa catalysis of fibrin cross-linking. The related pharmaceutical compositions and methods disclosed in the patent may be advantageously used to enhance fibrinolysis and the resolution of blood clots. He has 1 patent to his name.
Career Highlights
Throughout his career, Hank has worked with prominent companies in the biotechnology sector. He has been associated with Zymogenetics, Inc. and Novo Nordisk A/S, where he contributed to various innovative projects. His expertise in biochemistry has been instrumental in advancing research in hemostasis.
Collaborations
Hank has collaborated with several professionals in his field, including Robert R West and Teresa Martinez. These collaborations have fostered a productive environment for innovation and research.
Conclusion
Hank R Franklin's contributions to the field of biochemistry, particularly through his patent on Factor XIIIA inhibitors, highlight his role as an innovator in hemostasis. His work continues to influence the development of therapeutic solutions for blood clot management.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile